DESIGN, SETTING, AND PARTICIPANTS This active-comparator new-user cohort study used nationwide register data from Sweden and Denmark from 2013 to 2021
April 2025 | Volume 24 | Issue 4 | 413 | Copyright April 2025 Published online March 7, 2025 doi:10.36849/JDD.8605 Sophia Daniel BS a,b , Stephanie Waggett BS a,c , Elliott Lyles BS a , Pelin Sagut MD a,d , Parisa Shamaei Zadeh MSPH b , Anthony Marcelletti BHS b , Carol Stegura ME c , Lara Wine Lee MD PhD d a College of Graduate Studies, Medical University of South Carolina, Charleston, SC b College of Medicine, University of Kentucky, Lexington, KY c College of Medicine, Medical University of South Carolina, Charleston, SC d Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC Abstract Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss
GLP-1 is a hormone naturally produced in the body
